Condition (MeSH)
Lipoma
ClinicalTrials.gov lists 19 trials for Lipoma or a narrower condition beneath it. Kythera Biopharmaceuticals has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
19 of the 19 trials are tagged with Lipoma itself; the rest are tagged with a narrower condition beneath it.
When did Lipoma trials start? (10)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 5 |
| 2024 | 2 |
| 2021 | 1 |
| 2018 | 1 |
| 2016 | 2 |
| 2014 | 1 |
| 2012 | 1 |
| 2008 | 1 |
| 2007 | 3 |
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Lipoma trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 2 |
| Phase 2 | 4 |
| Phase 3 | 1 |
| Not applicable | 7 |
| Observational | 3 |
How many Lipoma trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 4 |
| Active, not recruiting | 1 |
| Completed | 10 |
| Unknown status | 3 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Lipoma trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Kythera Biopharmaceuticals | 2 |
| Assaf-Harofeh Medical Center | 1 |
| Espad Pharmed | 1 |
| Glonova Pharma Co., Ltd | 1 |
| Spectros Corporation | 1 |
Which drugs are being tested for Lipoma? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| KYBELLA | 1 |
| Ribociclib | 1 |
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Deoxycholic Acid Injection | 2 |
| Clostridium Histolyticum Collagenase | 2 |
| Ronkyla Plus | 1 |
| Warmed Sodium Chloride Injection | 1 |
| Cooled Sodium Chloride Injection | 1 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Lipoma trials report? (3)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Breast Cancer | 1 | 1 |
| Patella Fracture | 1 | 1 |
| Tibia Fracture | 1 | 1 |
Which publications cover Lipoma? (27)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| A critical analysis of surgery for occult tethered cord syndrome. | Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery | 2021 | Yes |
| Targeted therapy in patients with PIK3CA-related overgrowth syndrome. | Nature | 2018 | Yes |
| Erector Spinae Plane Block for Surgery of the Posterior Thoracic Wall in a Pediatric Patient. | Regional anesthesia and pain medicine | 2018 | Yes |
| Spinal column shortening for tethered cord syndrome associated with myelomeningocele, lumbosacral lipoma, and lipomyelomeningocele in children and young adults. | Journal of neurosurgery. Pediatrics | 2017 | Yes |
| Expanding indications for ESD: submucosal disease (SMT/carcinoid tumors). | Gastrointestinal endoscopy clinics of North America | 2014 | Yes |
Showing 5 of 27 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.